aleksandar-mijatovic-shutterstock-com

Aleksandar Mijatovic / Shutterstock.com

18 August 2015Americas

Pfizer’s Hospira buyout approved in Australia and Canada

Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

US and Brazil clear path for Pfizer’s Hospira buyout

26 August 2015 Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

More on this story

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

US and Brazil clear path for Pfizer’s Hospira buyout

26 August 2015 Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

More on this story

European Commission approves Pfizer’s buyout of Hospira

6 August 2015 The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

US and Brazil clear path for Pfizer’s Hospira buyout

26 August 2015 Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent